Literature DB >> 15848718

Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation.

A Hendawy1, A Hemdawy, C Pouteil-Noble, E Villar, P Boissonnat, L Sebbag.   

Abstract

The aim of the study was to analyze the etiology, the factors for progression of chronic renal failure to end-stage-renal disease (ESRD), and the influence of ESRD on the survival rate among a cohort of 59 heart transplant patients (HTP) referred for the management of chronic renal failure (CRF). At the time of the first nephrology consultation (6 +/- 4.25 years after cardiac transplantation) the mean creatininemia was 261.5 +/- 99 micromol/L and mean creatinine clearance (Cockcroft formula) was 32 +/- 15 mL/min. The cause of CRF were calcineurin inhibitor toxicity in 38.9% of patients, vascular events in 15.2%, hemolytic uremic syndrome in 5%, membranous glomerulopathy in 3.3%, diabetes in two patients, focal/segmental glomerulosclerosis in 3.3%, renal hypoplasia in 1.7%, and unknown in 27%. Evolution to ESRD occurred in 38.9% of patients: 17 patients started hemodialysis, three peritoneal dialysis, and two received a preemptive kidney transplantation. Creatininemia (micromol/L) at the time of nephrology referral was 229.2 +/- 72.6 versus 315.8 +/- 113.4 (P < .001) and creatinine clearance (mL/min) was 34.9 +/- 15.1 versus 27.3 +/- 13.7 (P = .049) for patients with CRF versus ESRD, respectively. Both proteinuria (g/24 hours) of 1 +/- 2.2 versus 2.3 +/- 1.8 (P = .02) and tobacco use in 35.1% versus 54.4% (P = .045) were significantly associated with progression of CRF, while age at the time of heart transplantation, cause of cardiac failure and renal failure, high blood pressure, type 2 diabetes, dyslipidemia, alcoholism, cirrhosis, and cerebral vascular accident were not. Death occurred in 18 HTP: 50% of patients with ESRD and 18.5% of patients with CRF-a 2.6 relative risk of of death in HTP patients with ESRD compared with HTP with CRF only (P < .01).

Entities:  

Mesh:

Year:  2005        PMID: 15848718     DOI: 10.1016/j.transproceed.2004.12.276

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

2.  End-stage kidney disease after pediatric nonrenal solid organ transplantation.

Authors:  Rebecca L Ruebner; Peter P Reese; Michelle R Denburg; Peter L Abt; Susan L Furth
Journal:  Pediatrics       Date:  2013-10-14       Impact factor: 7.124

3.  Marginal versus Standard Donors in Heart Transplantation: Proper Selection Means Heart Transplant Benefit.

Authors:  Olimpia Bifulco; Tomaso Bottio; Raphael Caraffa; Massimiliano Carrozzini; Alvise Guariento; Jonida Bejko; Marny Fedrigo; Chiara Castellani; Giuseppe Toscano; Giulia Lorenzoni; Vincenzo Tarzia; Dario Gregori; Massimo Cardillo; Francesca Puoti; Giuseppe Feltrin; Annalisa Angelini; Gino Gerosa
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

4.  Incidence of end-stage renal disease after heart transplantation and effect of its treatment on survival.

Authors:  Stefan Roest; Dennis A Hesselink; Dominika Klimczak-Tomaniak; Isabella Kardys; Kadir Caliskan; Jasper J Brugts; Alexander P W M Maat; Michał Ciszek; Alina A Constantinescu; Olivier C Manintveld
Journal:  ESC Heart Fail       Date:  2020-02-05

Review 5.  Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.

Authors:  Sangeeta Hingorani
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.